Literature DB >> 9257775

Evaluation of growth promotion and inhibition from mycobactins and nonmycobacterial siderophores (Desferrioxamine and FR160) in Mycobacterium aurum.

S Bosne-David1, L Bricard, F Ramiandrasoa, A DeRoussent, G Kunesch, A Andremont.   

Abstract

Heterologous mycobactins and the synthetic FR160 [N4-nonyl,N1,N8-bis(2,3-dihydroxybenzoyl) spermidine hydrobromide (C3 0H4 6N3, O6 Br)] promoted growth in Mycobacterium aurum in low concentrations. They were otherwise highly inhibitory, as opposed to homologous mycobactin, which was strictly growth promoting. Desferrioxamine B (Desferal) had no significant effect on growth.

Entities:  

Mesh：

Substances：

Year:  1997        PMID： 9257775      PMCID： PMC164019     

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN： 0066-4804            Impact factor:   5.191


  20 in total

1.  Mycobactin, a growth factor for Mycobacterium johnei. I. Isolation from Mycobacterium phlei.

Authors:  J FRANCIS; H M MACTURK; J MADINAVEITIA; G A SNOW
Journal:  Biochem J       Date:  1953-11       Impact factor: 3.857

2.  Effect of temperature on the rate of the transparent to opaque colony type transition in Mycobacterium avium.

Authors:  C L Woodley; H L David
Journal:  Antimicrob Agents Chemother       Date:  1976-01       Impact factor: 5.191

3.  Mode of action of GR69153, a novel catechol-substituted cephalosporin, and its interaction with the tonB-dependent iron transport system.

Authors:  P Silley; J W Griffiths; D Monsey; A M Harris
Journal:  Antimicrob Agents Chemother       Date:  1990-09       Impact factor: 5.191

4.  In vitro activities of novel catecholate siderophores against Plasmodium falciparum.

Authors:  B Pradines; F Ramiandrasoa; L K Basco; L Bricard; G Kunesch; J Le Bras
Journal:  Antimicrob Agents Chemother       Date:  1996-09       Impact factor: 5.191

5.  E-0702, a new cephalosporin, is incorporated into Escherichia coli cells via the tonB-dependent iron transport system.

Authors:  N A Watanabe; T Nagasu; K Katsu; K Kitoh
Journal:  Antimicrob Agents Chemother       Date:  1987-04       Impact factor: 5.191

Review 6.  Mycobactins: iron-chelating growth factors from mycobacteria.

Authors:  G A Snow
Journal:  Bacteriol Rev       Date:  1970-06

7.  Basis for lack of drug susceptibility of atypical mycobacteria.

Authors:  H L David
Journal:  Rev Infect Dis       Date:  1981 Sep-Oct

8.  Participation of iron on the growth inhibition of pathogenic strains of mycobacterium avium and M. paratuberculosis in serum.

Authors:  R Barclay; C Ratledge
Journal:  Zentralbl Bakteriol Mikrobiol Hyg A       Date:  1986-08

9.  Isolation, purification and structure of exochelin MS, the extracellular siderophore from Mycobacterium smegmatis.

Authors:  G J Sharman; D H Williams; D F Ewing; C Ratledge
Journal:  Biochem J       Date:  1995-01-01       Impact factor: 3.857

10.  Mechanism of Tuberculostasis in Mammalian Serum III. Neutralization of Serum Tuberculostasis by Mycobactin.

Authors:  I Kochan; N R Pellis; C A Golden
Journal:  Infect Immun       Date:  1971-04       Impact factor: 3.441
View more
  3 in total

Review 1.  Siderophore-based iron acquisition and pathogen control.

Authors:  Marcus Miethke; Mohamed A Marahiel
Journal:  Microbiol Mol Biol Rev       Date:  2007-09       Impact factor: 11.056

Review 2.  Utilization of microbial iron assimilation processes for the development of new antibiotics and inspiration for the design of new anticancer agents.

Authors:  Marvin J Miller; Helen Zhu; Yanping Xu; Chunrui Wu; Andrew J Walz; Anne Vergne; John M Roosenberg; Garrett Moraski; Albert A Minnick; Julia McKee-Dolence; Jingdan Hu; Kelley Fennell; E Kurt Dolence; Li Dong; Scott Franzblau; Francois Malouin; Ute Möllmann
Journal:  Biometals       Date:  2009-01-07       Impact factor: 2.949

Review 3.  Tuning the Anti(myco)bacterial Activity of 3-Hydroxy-4-pyridinone Chelators through Fluorophores.

Authors:  Maria Rangel; Tânia Moniz; André M N Silva; Andreia Leite
Journal:  Pharmaceuticals (Basel)       Date:  2018-10-20
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.